$PLRX
PLIANT THERAPEUTICS, INC. Stock $plrx

$plrx Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000174647322000027 Filed on August 08, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$1.482M	$4.989M	$1.249M
YoY Change	-7.38%	178.87%	-42.55%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.823M	$8.296M	$8.579M
YoY Change	15.02%	51.53%	30.58%
% of Gross Profit
Research & Development	$24.61M	$26.34M	$20.88M
YoY Change	16.88%	37.03%	12.71%
% of Gross Profit
Depreciation & Amortization	$500.0K	$500.0K	$500.0K
YoY Change	25.0%	25.0%	25.0%
% of Gross Profit
Operating Expenses	$33.43M	$34.63M	$29.46M
YoY Change	16.38%	40.25%	17.4%
Operating Profit	-$31.95M	-$29.64M	-$28.21M
YoY Change	17.83%	29.42%	23.09%
Interest Expense	$1.332M	$96.00K	$111.0K
YoY Change	1858.82%	31.51%	85.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$30.62M	-$29.55M	-$28.10M
YoY Change	13.2%	29.41%	22.92%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$30.62M	-$29.55M	-$28.10M
YoY Change	13.2%	29.41%	22.94%
Net Earnings / Revenue	-2065.79%	-592.22%	-2249.8%
Basic Earnings Per Share	-$0.65	-$0.82	-$0.78
Diluted Earnings Per Share	-$0.65	-$0.82	-$0.78
COMMON SHARES
Basic Shares Outstanding	48.68M shares	36.17M shares	36.12M shares
Diluted Shares Outstanding	46.80M shares	36.17M shares	36.12M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$360.2M	$163.6M	$178.3M
YoY Change	62.97%	-32.95%	-32.5%
Cash & Equivalents	$44.62M	$25.07M	$32.55M
Short-Term Investments	$315.6M	$138.5M	$145.7M
Other Short-Term Assets	$4.159M	$4.857M	$5.751M
YoY Change	-28.87%	0.66%	36.93%
Inventory
Prepaid Expenses
Receivables	$1.482M	$4.989M	$1.249M
Other Receivables	$83.00K	$83.00K	$83.00K
Total Short-Term Assets	$366.0M	$173.5M	$185.4M
YoY Change	60.1%	-30.79%	-31.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.799M	$4.534M	$4.738M
YoY Change	1.98%	3.82%	11.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$397.0K	$913.0K	$835.0K
YoY Change	-52.23%	44.92%	85.14%
Total Long-Term Assets	$11.22M	$11.09M	$11.66M
YoY Change	102.56%	121.99%	147.17%
TOTAL ASSETS
Total Short-Term Assets	$366.0M	$173.5M	$185.4M
Total Long-Term Assets	$11.22M	$11.09M	$11.66M
Total Assets	$377.2M	$184.6M	$197.0M
YoY Change	61.11%	-27.8%	-28.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.206M	$3.116M	$4.684M
YoY Change	23.07%	12.74%	62.3%
Accrued Expenses	$20.31M	$17.40M	$11.63M
YoY Change	96.76%	112.97%	57.88%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.649M	$2.042M	$1.999M
YoY Change
Total Short-Term Liabilities	$26.16M	$22.55M	$18.31M
YoY Change	102.41%	106.3%	78.62%
LONG-TERM LIABILITIES
Long-Term Debt	$14.03M	$14.28M	$4.920M
YoY Change
Other Long-Term Liabilities	$4.126M	$4.407M	$4.920M
YoY Change	445.77%	448.13%	489.22%
Total Long-Term Liabilities	$14.03M	$14.28M	$4.920M
YoY Change	1755.29%	1675.87%	489.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.16M	$22.55M	$18.31M
Total Long-Term Liabilities	$14.03M	$14.28M	$4.920M
Total Liabilities	$40.19M	$36.83M	$23.23M
YoY Change	193.74%	213.83%	109.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$303.4M	-$272.7M	-$243.2M
YoY Change	59.19%	66.8%	72.86%
Common Stock	$642.8M	$421.8M	$417.9M
YoY Change	56.38%	3.5%	3.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$337.0M	$147.8M	$173.8M
YoY Change
Total Liabilities & Shareholders Equity	$377.2M	$184.6M	$197.0M
YoY Change	61.11%	-27.8%	-28.42%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$30.62M	-$29.55M	-$28.10M
YoY Change	13.2%	29.41%	22.94%
Depreciation, Depletion And Amortization	$500.0K	$500.0K	$500.0K
YoY Change	25.0%	25.0%	25.0%
Cash From Operating Activities	-$18.50M	-$24.40M	-$20.50M
YoY Change	-17.82%	25.77%	50.0%
INVESTING ACTIVITIES
Capital Expenditures	-$696.0K	-$254.0K	$644.0K
YoY Change	45.0%	-60.37%	166.12%
Acquisitions
YoY Change
Other Investing Activities	-$177.6M	$6.749M	$2.175M
YoY Change	-644.98%	59.66%	-82.56%
Cash From Investing Activities	-$178.3M	$6.495M	$1.531M
YoY Change	-655.3%	81.12%	-87.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	216.3M	10.43M	-$153.0K
YoY Change	48073.05%	5330.21%	-111.17%
NET CHANGE
Cash From Operating Activities	-18.50M	-24.40M	-$20.50M
Cash From Investing Activities	-178.3M	6.495M	$1.531M
Cash From Financing Activities	216.3M	10.43M	-$153.0K
Net Change In Cash	19.55M	-7.475M	-$19.12M
YoY Change	94.71%	-52.14%	30249.21%
FREE CASH FLOW
Cash From Operating Activities	-$18.50M	-$24.40M	-$20.50M
Capital Expenditures	-$696.0K	-$254.0K	$644.0K
Free Cash Flow	-$17.80M	-$24.14M	-$21.14M
YoY Change	-19.19%	28.71%	52.02%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001746473
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Entity File Number EntityFileNumber	001-39303
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	PLIANT THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-4272481
	dei	Entity Address Address Line1 EntityAddressAddressLine1	260 Littlefield Avenue
	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco,
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	481-6770
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	PLRX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48681962	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25070000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51665000	usd
CY2022Q2	us-gaap	Short Term Investments ShortTermInvestments	138527000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	148931000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4989000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1998000	usd
CY2022Q2	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	83000	usd
CY2021Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	83000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4857000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6764000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	173526000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	209441000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4534000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4606000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5646000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6330000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	913000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	838000	usd
CY2022Q2	us-gaap	Assets Assets	184619000	usd
CY2021Q4	us-gaap	Assets Assets	221215000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3116000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2971000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17395000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11991000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2042000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1869000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	22553000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16831000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4407000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5325000	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	9871000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	0	usd
CY2022Q2	us-gaap	Liabilities Liabilities	36831000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	22156000	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36182297	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36182297	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36083301	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36083301	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	421781000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	414348000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-272737000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-215091000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1259000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-201000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	147788000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	199059000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	184619000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	221215000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4989000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1789000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6238000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3963000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26335000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19218000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47216000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37745000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8296000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5475000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16875000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12041000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	34631000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	24693000	usd
	us-gaap	Operating Expenses OperatingExpenses	64091000	usd
	us-gaap	Operating Expenses OperatingExpenses	49786000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-29642000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-22904000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-57853000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-45823000	usd
CY2022Q2	plrx	Interest And Other Income Net InterestAndOtherIncomeNet	96000	usd
CY2021Q2	plrx	Interest And Other Income Net InterestAndOtherIncomeNet	73000	usd
	plrx	Interest And Other Income Net InterestAndOtherIncomeNet	207000	usd
	plrx	Interest And Other Income Net InterestAndOtherIncomeNet	136000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-29546000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-22831000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-57646000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-45687000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29546000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22831000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-57646000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-45687000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.59
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.28
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.82
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.59
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.28
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36173135	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35746922	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36144944	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35726393	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36173135	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35746922	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36144944	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35726393	shares
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-29546000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-22831000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-57646000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-45687000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-309000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-12000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1058000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-309000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-12000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1058000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29855000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22843000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-58704000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45685000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	199059000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	51000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3531000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-749000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-28100000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	173793000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	446000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3403000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-309000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-29546000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	147788000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	283061000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1370000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2578000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	14000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-22856000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	264169000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	372000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2280000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-12000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-22831000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	243980000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-57646000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-45687000	usd
	us-gaap	Depreciation Depreciation	914000	usd
	us-gaap	Depreciation Depreciation	729000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6934000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4858000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	684000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	441000	usd
	plrx	Other Losses OtherLosses	443000	usd
	plrx	Other Losses OtherLosses	529000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2991000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7449000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1907000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	328000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	202000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	741000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5404000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1333000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-745000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-467000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-44894000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33068000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	78048000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	138832000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	86972000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	155529000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	898000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	881000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	8026000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	15816000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	498000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1741000	usd
	plrx	Payments Of Deferred Offering Costs PaymentsOfDeferredOfferingCosts	75000	usd
	plrx	Payments Of Deferred Offering Costs PaymentsOfDeferredOfferingCosts	179000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	150000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	10000000	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10273000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1562000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-26595000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15690000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51665000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50882000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25070000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35192000	usd
	us-gaap	Interest Paid Net InterestPaidNet	72000	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	82000	usd
	plrx	Reclassification Of Restricted Stock Awards From Liabilities To Common Stock Upon Vesting ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting	1000	usd
	plrx	Reclassification Of Restricted Stock Awards From Liabilities To Common Stock Upon Vesting ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting	5000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1058000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	2000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses as well as the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to stock-based compensation expense and accruals for research and development costs. The Company assesses estimates on an ongoing basis, however, actual results could materially differ from those estimates.</span></div>
CY2022Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	154364000	usd
	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain	0	usd
	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	1259000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	153105000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	183958000	usd
CY2021	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain	1000	usd
CY2021	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	202000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	183757000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10465000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9625000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5931000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5019000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4534000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4606000	usd
CY2022Q2	us-gaap	Depreciation Depreciation	500000	usd
CY2021Q2	us-gaap	Depreciation Depreciation	400000	usd
	us-gaap	Depreciation Depreciation	900000	usd
	us-gaap	Depreciation Depreciation	700000	usd
CY2022Q2	plrx	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	2448000	usd
CY2021Q4	plrx	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	2819000	usd
CY2022Q2	us-gaap	Prepaid Insurance PrepaidInsurance	849000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2585000	usd
CY2022Q2	plrx	Prepaid Licenses Current PrepaidLicensesCurrent	1028000	usd
CY2021Q4	plrx	Prepaid Licenses Current PrepaidLicensesCurrent	819000	usd
CY2022Q2	us-gaap	Interest Receivable Current InterestReceivableCurrent	320000	usd
CY2021Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	385000	usd
CY2022Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	212000	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	156000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4857000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6764000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3520000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5216000	usd
CY2022Q2	plrx	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	13094000	usd
CY2021Q4	plrx	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	5868000	usd
CY2022Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	781000	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	907000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17395000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11991000	usd
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	0	usd
CY2021	us-gaap	Interest Expense InterestExpense	0	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	5455000	usd
CY2022Q2	plrx	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	4545000	usd
CY2022Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3403000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2280000	usd
CY2022Q2	plrx	Number Of Classes Of Stock Authorized NumberOfClassesOfStockAuthorized	2	class
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4858000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6934000	usd
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	The holders of shares of common stock are entitled to one vote for each share of common stock held at any meeting of stockholders and at the time of any written action in lieu of a meeting.
	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2022Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10498179	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8467491	shares
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q2	plrx	Valuation Allowance As Percentage On Deferred Tax Assets ValuationAllowanceAsPercentageOnDeferredTaxAssets	1
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
	plrx	Contractual Arrangements Cancellation Period ContractualArrangementsCancellationPeriod	P30D
CY2018Q1	plrx	Period Of Base Rent Abatement PeriodOfBaseRentAbatement	P2M
CY2018Q1	plrx	Base Rent Abated Amount BaseRentAbatedAmount	200000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	600000	usd
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	600000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1100000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1200000	usd
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	200000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	300000	usd
CY2021Q2	us-gaap	Variable Lease Cost VariableLeaseCost	300000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	500000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1200000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1200000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1237000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2413000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2365000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1203000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	0	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7218000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	769000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	6449000	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M24D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.079
CY2021Q2	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-45687000	usd
CY2022Q2	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	400000	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	400000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5420264	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3912829	shares
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-29546000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-22831000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-57646000	usd
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.82
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35726393	shares
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29546000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22831000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-57646000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-45687000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36173135	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35746922	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36144944	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35726393	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36173135	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35746922	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36144944	shares
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.59
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.28
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.59
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.28

Files In Submission

Name	View Source	Status
0001746473-22-000027-index-headers.html	Edgar Link	pending
0001746473-22-000027-index.html	Edgar Link	pending
0001746473-22-000027.txt	Edgar Link	pending
0001746473-22-000027-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
plrx-20220630.htm	Edgar Link	pending
plrx-20220630.xsd	Edgar Link	pending
plrx-20220630xex3111.htm	Edgar Link	pending
plrx-20220630xex3121.htm	Edgar Link	pending
plrx-20220630xex3211.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
plrx-20220630_def.xml	Edgar Link	unprocessable
plrx-20220630_pre.xml	Edgar Link	unprocessable
plrx-20220630_htm.xml	Edgar Link	completed
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
plrx-20220630_cal.xml	Edgar Link	unprocessable
plrx-20220630_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLRX
PLIANT THERAPEUTICS, INC. Stock $plrx

2022 Q3 Form 10-Q Financial Statement

#000174647322000027 Filed on August 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLRX PLIANT THERAPEUTICS, INC. Stock $plrx

2022 Q3 Form 10-Q Financial Statement

#000174647322000027 Filed on August 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLRX
PLIANT THERAPEUTICS, INC. Stock $plrx